MapLight Therapeutics, Inc.·4

Apr 17, 4:05 PM ET

Malenka Robert C. 4

4 · MapLight Therapeutics, Inc. · Filed Apr 17, 2026

Research Summary

AI-generated summary of this filing

Updated

MapLight (MPLT) Director Robert Malenka Sells 8,593 Shares

What Happened
Robert C. Malenka, a director of MapLight Therapeutics, sold 8,593 shares of MPLT on April 15, 2026. The weighted average sale price was $26.90 per share, resulting in gross proceeds of approximately $231,152. This was a sale (S), not a purchase.

Key Details

  • Transaction date: 2026-04-15; Form 4 filed: 2026-04-17 (timely filing).
  • Price: weighted average $26.90; individual sale prices ranged from $26.35 to $27.29.
  • Shares sold: 8,593; total proceeds ≈ $231,152.
  • Shares after transaction: not specified in the provided filing excerpt.
  • Footnotes of note:
    • F1: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Dec 26, 2025.
    • F2: Weighted-average price reported; seller can provide breakdown of shares sold at each price on request.
    • F3: Shares were held by the Robert C. Malenka Living Trust (he is sole trustee with voting/dispositive power).

Context
Sales under Rule 10b5-1 plans are pre-scheduled trading arrangements and are commonly used by insiders to sell shares without regard to short-term company developments; they do not, by themselves, indicate a change in the insider’s view of the company. For retail investors, purchases typically carry more direct bullish signaling than routine, pre-planned sales.

Insider Transaction Report

Form 4
Period: 2026-04-15
Transactions
  • Sale

    Voting Common Stock

    [F1][F2]
    2026-04-15$26.90/sh8,593$231,152316,466 total
Holdings
  • Voting Common Stock

    [F3]
    (indirect: See footnote)
    31,672
Footnotes (3)
  • [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
  • [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-04-17

Documents

1 file
  • 4
    form4-04172026_040402.xmlPrimary